Literature DB >> 8411377

Cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region in transgenic mice and its modulation by tetradecanoyl phorbol acetate and glucocorticoids.

A Cid1, P Auewarakul, A Garcia-Carranca, R Ovseiovich, H Gaissert, L Gissmann.   

Abstract

The upstream regulatory region (URR) of human papillomavirus type 18 (HPV-18) harbors transcriptional promoter and enhancer elements which are thought to determine the cell-type specificity of the virus. In order to study the regulation of HPV-18 expression in vivo, we constructed transgenic mice carrying the bacterial lacZ gene under the control of the HPV-18 URR. Analysis of beta-galactosidase activity by histochemical staining of tissue sections of four independent transgenic mice showed that the viral promoter was specifically active in epithelial cells within a variety of organs (e.g., tongue, ovary, uterus, testis, and small intestine). Very strong staining was observed in newborn transgenic mice in contrast to a weak activity found during fetal life. Determination of beta-galactosidase activity in crude extracts from tissues of three lines of transgenic mice proved to be a useful tool for a quantitative analysis of transgene expression. In mice from two different transgenic lines treated with dexamethasone such measurements revealed a biphasic effect of the hormone on the activity of the enzyme in the stratified epithelium of the tongue (transient increase followed by a decrease). Northern (RNA) blot analysis showed similar changes in beta-galactosidase mRNA in that tissue. Treatment with tetradecanoyl phorbol acetate (TPA) led to a twofold increase in both enzymatic activity and mRNA levels. Finally, combined treatments with dexamethasone and TPA showed that both factors interfered with each other in their respective effects on transgene expression, suggesting that a cross-talk mechanism between transcription factors could be involved in the regulation of the HPV-18 URR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411377      PMCID: PMC238115     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer.

Authors:  J Price; D Turner; C Cepko
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Electroporation for the efficient transfection of mammalian cells with DNA.

Authors:  G Chu; H Hayakawa; P Berg
Journal:  Nucleic Acids Res       Date:  1987-02-11       Impact factor: 16.971

3.  The effect of DNA methylation on gene regulation of human papillomaviruses.

Authors:  F Rösl; A Arab; B Klevenz; H zur Hausen
Journal:  J Gen Virol       Date:  1993-05       Impact factor: 3.891

4.  Bovine papillomavirus genome elicits skin tumours in transgenic mice.

Authors:  M Lacey; S Alpert; D Hanahan
Journal:  Nature       Date:  1986 Aug 14-20       Impact factor: 49.962

5.  Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor.

Authors:  B H Cochran; J Zullo; I M Verma; C D Stiles
Journal:  Science       Date:  1984-11-30       Impact factor: 47.728

6.  Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression.

Authors:  H zur Hausen
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

7.  Environmental induction of differentiation-specific keratins in malignant mouse keratinocyte lines.

Authors:  D Breitkreutz; J Hornung; J Pöhlmann; L Brown-Bierman; A Bohnert; P E Bowden; N E Fusenig
Journal:  Eur J Cell Biol       Date:  1986-12       Impact factor: 4.492

8.  Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos.

Authors:  J R Sanes; J L Rubenstein; J F Nicolas
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

9.  Characterization of a cell type-specific enhancer found in the human papilloma virus type 18 genome.

Authors:  F V Swift; K Bhat; H B Younghusband; H Hamada
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

10.  Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes.

Authors:  A Schneider-Gädicke; E Schwarz
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

View more
  6 in total

1.  The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells.

Authors:  A Schmitt; A Rochat; R Zeltner; L Borenstein; Y Barrandon; F O Wettstein; T Iftner
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.

Authors:  Angel Cid-Arregui; Victoria Juárez; Harald zur Hausen
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors.

Authors:  P Auewarakul; L Gissmann; A Cid-Arregui
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

4.  Heparin (GAG-hed) inhibits LCR activity of human papillomavirus type 18 by decreasing AP1 binding.

Authors:  Rita Villanueva; Néstor Morales-Peza; Irma Castelán-Sánchez; Enrique García-Villa; Rocio Tapia; Angel Cid-Arregui; Alejandro García-Carrancá; Esther López-Bayghen; Patricio Gariglio
Journal:  BMC Cancer       Date:  2006-08-31       Impact factor: 4.430

5.  E6/E7 oncogenes in epithelial suprabasal layers and estradiol promote cervical growth and ear regeneration.

Authors:  C García; D Hernández-García; C Valencia; V Rojo-León; J-R Pérez-Estrada; M Werner; L Covarrubias
Journal:  Oncogenesis       Date:  2017-08-28       Impact factor: 7.485

Review 6.  Regulation of HPV transcription.

Authors:  Aline Lopes Ribeiro; Amanda Schiersner Caodaglio; Laura Sichero
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.